Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Liquid Tricaprilin in Healthy Subjects
NCT05408780Phase 1Completed
- Sponsor
- Cerecin
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tricaprilin in Alzheimer's disease (AD) (3 arms), sponsored by Cerecin. Primary endpoints: Area under the concentration-time curve (AUC) of total ketones (β-hydroxybutyrate and acetoacetate) and Incidence of Treatment Emergent Adverse Events. Started Jul 2022; status: completed.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05408780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408780.